A second round of studies has begun on a skin tissue product developed by a Madison company, designed to treat patients with serious burns.
The first patient has been enrolled in a Phase 2 study of StrataGraft, the skin tissue developed by Madison-based Stratatech, now part of Mallinckrodt, a global pharmaceutical company.
The study is expected to follow 20 patients to evaluate the success of StrataGraft in healing their wounds over a three-month period. The study is expected to be completed by late 2018, Mallinckrodt said.
“We are dedicated to providing regenerative medicine advanced therapies to patients with serious complex skin wounds, such as burns and other trauma,” said Lynn Allen-Hoffmann, senior vice president, regenerative medicine at Mallinckrodt and founder of Stratatech.
Mallinckrodt bought Stratatech for $76 million in August 2016.
An earlier round of clinical tests, conducted by Stratatech, showed StrataGraft healed the wounds of nearly 30 patients with deep burns at least as well as their own skin did.
The research is being supported by a contract with the U.S. Army Medical Research and Materiel Command.